Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.

Détails

ID Serval
serval:BIB_8B9FB9947BCD
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
Périodique
Current Opinion in Oncology
Auteur(s)
Wagner A.D., Moehler M.
ISSN
1531-703X (Electronic)
ISSN-L
1040-8746
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
21
Numéro
4
Pages
381-385
Langue
anglais
Notes
Publication types: Journal Article ; Review Publication Status: ppublish
Résumé
PURPOSE OF REVIEW: Many chemotherapeutic drugs, including fluoropyrimidines, platinums, CPT-11, taxanes and adriamycin have single-agent activity in advanced gastric cancer. Although combination chemotherapy has been shown to be more effective than single agents, response rates between 30 and 50% have not fulfilled their promise as progression-free survival from the best combinations ranges between 3 and 7 months and overall survival between 8 and 11 months. The development of targeted therapies in gastric cancer clearly stays behind the integration of these novel agents into new treatment concepts for patients with colorectal cancer. This review summarizes the experience and major recent advances in the development of targeted therapies in advanced gastric cancer.
RECENT FINDINGS: Recent publications on targeted therapies in gastric cancer are limited to nonrandomized phase I or II trials. The majority of agents tested were angiogenesis inhibitors or agents targeting the epidermal growth factor receptors epidermal growth factor receptor 1 and HER2.
SUMMARY: Adequately powered, randomized phase III trials are necessary to define the clinical role of targeted therapies in advanced gastric cancer. Biomarker studies to correlate with treatment outcomes will be critical to identify patients who benefit most from chemotherapy and targeted therapy.
Mots-clé
Angiogenesis Inhibitors/therapeutic use, Clinical Trials, Phase III as Topic, Drug Delivery Systems, Humans, Neovascularization, Pathologic/drug therapy, Protein Kinase Inhibitors/therapeutic use, Randomized Controlled Trials as Topic, Receptor, Epidermal Growth Factor/antagonists & inhibitors, Receptor, erbB-2/antagonists & inhibitors, Stomach Neoplasms/blood supply, Stomach Neoplasms/drug therapy
Pubmed
Web of science
Création de la notice
29/07/2009 9:27
Dernière modification de la notice
03/03/2018 19:12
Données d'usage